PARTNER 3 has been one of the most closely watched clinical trials in cardiology for many years now. Michael J. Mack, MD, presented a seven-year update during a packed session at TCT 2025. 

The Cardiovascular Research Foundation and Fogarty Innovation are joining forces to help innovative researchers and technologies flourish in today's competitive medtech industry. The two organizations made the partnership official at TCT 2025 in San Francisco. 

The SELUTION SLR Drug-Eluting Balloon was the topic of two different late-breaking clinical trials at TCT 2025. Both studies found that the device was noninferior to traditional treatments after one year. Long-term data are still needed. 

The guidewire was built specifically with Medtronic's own Evolut platform in mind. However, it is also compatible with all other commercially available TAVR systems.

The flexible device is attached to the inner wall of the left ventricle during a minimally invasive procedure. It was designed to reduce the size of the left ventricle over time.

Researchers tracked patients for two years, using echocardiography to confirm the devices had completely vanished. Additional studies will still be required.

PCI Navigator from Heartflow was designed to help cardiologists plan ahead for percutaneous coronary interventions before they even step foot into the cath lab. It assesses a patient’s CCTA results and creates a state-of-the-art 3D model.

In some cases, researchers noted, CABG may be a better treatment option. The group emphasized that alternative therapies are still needed to improve patient care.